BrainTrain consortium

Eight leading EU institutes (Amsterdam, London, Paris, Heidelberg, Stockholm, Magdeburg, Leuven and Trieste) together with the Japanese RIKEN, five commercial partners and FENS have formed BrainTrain ITN. Partners were selected on their outstanding publication records and ability to integrate different disciplines. BrainTrain builded on our knowledge of genome information and exploits innovative technologies and infrastructure to integrate this to unravel the (dys)function of living neurons, networks and the whole brain. Local specialists offered network-wide training and meetings. Our existing EU funded resources (IP EUsynapse, NeuroCypres and Neuromics EST) will provide an excellent, multicultural and inspiring environment for a new generation of integrative neuroscientists.

BrainTrain delivered 17 skilled ESR prepared for future challenges in neuroscience with optimal career opportunities and the ability to contribute to the fight against brain disorders.







  • Research teams

    To reach its objectives, the BrainTrain research program is composed of 5 scientific Research Teams, see list below, with 3 trainees each.
  • Genetics of the brain

    The increasing prevalence for neurodegenerative disease in our aging population poses a growing problem for healthcare.
    >Read more
  • The synaptic interactome

    Many brain disorders are to be considered 'synaptic diseases" or 'synaptopathies' and cellular function of synapses.
    >Read more
  • Functional genomic of the synapse

    The synapse is a specialized structure between two neurons at which basal neuronal communication takes place.
    >Read more
  • Synaptic plasticity

    In neuropsychiatric disorders associated with reduced cognitive abilities, such as age-related cognitive decline, but also mental retardation, the ability of synapses to alter their strength is strongly affected.
    >Read more
  • Transmission and behavioral function

    The etiology of many disorders including age-related cognitive decline and neurodegenerative disorders such as dementia and Parkinson’s disease is still poorly understood.
    >Read more